These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 17969568

  • 1. [Inhaled corticosteroids in patients with COPD: maintain current guidelines].
    Heijdra YF.
    Ned Tijdschr Geneeskd; 2007 Oct 06; 151(40):2195-7. PubMed ID: 17969568
    [Abstract] [Full Text] [Related]

  • 2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 3. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP.
    Am J Med; 2006 Oct 22; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [Abstract] [Full Text] [Related]

  • 4. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.
    Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ.
    COPD; 2007 Jun 22; 4(2):127-34. PubMed ID: 17530506
    [Abstract] [Full Text] [Related]

  • 5. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun 22; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 6. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
    Fang LZ, Liang X, Zhang JQ, Liu L, Fu WP, Zhao ZH, Dai LM.
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov 22; 31(11):811-4. PubMed ID: 19080533
    [Abstract] [Full Text] [Related]

  • 7. [Friend or foe: combination therapy with inhaled corticosteroids and long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD)].
    Gillissen A, Gessner C, Hoheisel G, Juergens U.
    Pneumologie; 2008 Jul 22; 62(7):430-7. PubMed ID: 18398787
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL, Baker EL, Coleman CI.
    Pharmacotherapy; 2009 Aug 22; 29(8):891-905. PubMed ID: 19637942
    [Abstract] [Full Text] [Related]

  • 9. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA, Donohue JF.
    Semin Respir Crit Care Med; 2010 Jun 22; 31(3):321-33. PubMed ID: 20496301
    [Abstract] [Full Text] [Related]

  • 10. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
    Cyr MC, Beauchesne MF, Lemière C, Aaron SD, Blais L.
    Ann Pharmacother; 2010 Apr 22; 44(4):613-22. PubMed ID: 20233915
    [Abstract] [Full Text] [Related]

  • 11. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 22; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 12. Adding long-acting beta-agonists to inhaled corticosteroids after discharge from the emergency department for acute asthma: a randomized controlled trial.
    Rowe BH, Wong E, Blitz S, Diner B, Mackey D, Ross S, Senthilselvan A.
    Acad Emerg Med; 2007 Oct 22; 14(10):833-40. PubMed ID: 17898245
    [Abstract] [Full Text] [Related]

  • 13. [Practice guideline 'Medical treatment of COPD'].
    Dekhuijzen PN, Broeders ME, Tuut MK, Grol MH.
    Ned Tijdschr Geneeskd; 2008 Jun 28; 152(26):1465-8. PubMed ID: 18666664
    [Abstract] [Full Text] [Related]

  • 14. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    Gordon E, Lazarus SC.
    J Allergy Clin Immunol; 2009 Nov 28; 124(5):873-80; quiz 881-2. PubMed ID: 19895979
    [Abstract] [Full Text] [Related]

  • 15. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA.
    Pulm Pharmacol Ther; 2008 Nov 28; 21(3):540-50. PubMed ID: 18280761
    [Abstract] [Full Text] [Related]

  • 16. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists.
    Mapel DW, Hurley JS, Roblin D, Roberts M, Davis KJ, Schreiner R, Frost FJ.
    Respir Med; 2006 Apr 28; 100(4):595-609. PubMed ID: 16199151
    [Abstract] [Full Text] [Related]

  • 17. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM, White CM, Coleman CI.
    Clin Ther; 2008 Aug 28; 30(8):1416-25. PubMed ID: 18803985
    [Abstract] [Full Text] [Related]

  • 18. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar 28; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 19. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 28; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 20. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 28; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.